Selected research
Industry Research
Intraveno (IV) Iron Drugs Industry Research Report 2026
Market perspective
The global Intraveno (IV) Iron Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Intraveno (IV) Iron Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Intraveno (IV) Iron Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Intraveno (IV) Iron Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Intraveno (IV) Iron Drugs include Sanofi, Vifor Pharma, Pharmacosmos, Luitpold Pharmaceuticals, Galenica, Fresenius Medical Care, American Regent, AMAG Pharmaceuticals and Allergan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Intraveno (IV) Iron Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Intraveno (IV) Iron Drugs Market by Company
Sanofi
Vifor Pharma
Pharmacosmos
Luitpold Pharmaceuticals
Galenica
Fresenius Medical Care
American Regent
AMAG Pharmaceuticals
Allergan
Actavis
Intraveno (IV) Iron Drugs Segment by Type
Low Molecular Weight Iron Dextran
Ferric Gluconate
Ferric Carboxyl Maltose
Iron Sucrose
Intraveno (IV) Iron Drugs Segment by Application
Ambulatory Surgical Centers
Hospitals
Diagnostic Centers
Intraveno (IV) Iron Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intraveno (IV) Iron Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Intraveno (IV) Iron Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intraveno (IV) Iron Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Intraveno (IV) Iron Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Intraveno (IV) Iron Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Intraveno (IV) Iron Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Low Molecular Weight Iron Dextran
- Ferric Gluconate
- Ferric Carboxyl Maltose
- Iron Sucrose
Applications
- Ambulatory Surgical Centers
- Hospitals
- Diagnostic Centers
Companies covered
- Sanofi
- Vifor Pharma
- Pharmacosmos
- Luitpold Pharmaceuticals
- Galenica
- Fresenius Medical Care
- American Regent
- AMAG Pharmaceuticals
- Allergan
- Actavis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Intraveno (IV) Iron Drugs Market Size (2021-2032)
- 2.2.2 Global Intraveno (IV) Iron Drugs Sales (2021-2032)
- 2.2.3 Global Intraveno (IV) Iron Drugs Market Average Price (2021-2032)
- 2.3 Intraveno (IV) Iron Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Low Molecular Weight Iron Dextran
- 2.3.3 Ferric Gluconate
- 2.3.4 Ferric Carboxyl Maltose
- 2.3.5 Iron Sucrose
- 2.4 Intraveno (IV) Iron Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Ambulatory Surgical Centers
- 2.4.3 Hospitals
- 2.4.4 Diagnostic Centers
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Intraveno (IV) Iron Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Intraveno (IV) Iron Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Intraveno (IV) Iron Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Intraveno (IV) Iron Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Intraveno (IV) Iron Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Intraveno (IV) Iron Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Intraveno (IV) Iron Drugs, Product Type & Application
- 3.8 Global Manufacturers of Intraveno (IV) Iron Drugs, Established Date
- 3.9 Global Intraveno (IV) Iron Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Intraveno (IV) Iron Drugs Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 Vifor Pharma
- 4.2.1 Vifor Pharma Company Information
- 4.2.2 Vifor Pharma Business Overview
- 4.2.3 Vifor Pharma Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Vifor Pharma Intraveno (IV) Iron Drugs Product Portfolio
- 4.2.5 Vifor Pharma Recent Developments
- 4.3 Pharmacosmos
- 4.3.1 Pharmacosmos Company Information
- 4.3.2 Pharmacosmos Business Overview
- 4.3.3 Pharmacosmos Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pharmacosmos Intraveno (IV) Iron Drugs Product Portfolio
- 4.3.5 Pharmacosmos Recent Developments
- 4.4 Luitpold Pharmaceuticals
- 4.4.1 Luitpold Pharmaceuticals Company Information
- 4.4.2 Luitpold Pharmaceuticals Business Overview
- 4.4.3 Luitpold Pharmaceuticals Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Luitpold Pharmaceuticals Intraveno (IV) Iron Drugs Product Portfolio
- 4.4.5 Luitpold Pharmaceuticals Recent Developments
- 4.5 Galenica
- 4.5.1 Galenica Company Information
- 4.5.2 Galenica Business Overview
- 4.5.3 Galenica Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Galenica Intraveno (IV) Iron Drugs Product Portfolio
- 4.5.5 Galenica Recent Developments
- 4.6 Fresenius Medical Care
- 4.6.1 Fresenius Medical Care Company Information
- 4.6.2 Fresenius Medical Care Business Overview
- 4.6.3 Fresenius Medical Care Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Fresenius Medical Care Intraveno (IV) Iron Drugs Product Portfolio
- 4.6.5 Fresenius Medical Care Recent Developments
- 4.7 American Regent
- 4.7.1 American Regent Company Information
- 4.7.2 American Regent Business Overview
- 4.7.3 American Regent Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 American Regent Intraveno (IV) Iron Drugs Product Portfolio
- 4.7.5 American Regent Recent Developments
- 4.8 AMAG Pharmaceuticals
- 4.8.1 AMAG Pharmaceuticals Company Information
- 4.8.2 AMAG Pharmaceuticals Business Overview
- 4.8.3 AMAG Pharmaceuticals Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 AMAG Pharmaceuticals Intraveno (IV) Iron Drugs Product Portfolio
- 4.8.5 AMAG Pharmaceuticals Recent Developments
- 4.9 Allergan
- 4.9.1 Allergan Company Information
- 4.9.2 Allergan Business Overview
- 4.9.3 Allergan Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Allergan Intraveno (IV) Iron Drugs Product Portfolio
- 4.9.5 Allergan Recent Developments
- 4.10 Actavis
- 4.10.1 Actavis Company Information
- 4.10.2 Actavis Business Overview
- 4.10.3 Actavis Intraveno (IV) Iron Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Actavis Intraveno (IV) Iron Drugs Product Portfolio
- 4.10.5 Actavis Recent Developments
5 Global Intraveno (IV) Iron Drugs Market Scenario by Region
- 5.1 Global Intraveno (IV) Iron Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Intraveno (IV) Iron Drugs Sales by Region: 2021-2032
- 5.2.1 Global Intraveno (IV) Iron Drugs Sales by Region: 2021-2026
- 5.2.2 Global Intraveno (IV) Iron Drugs Sales by Region: 2027-2032
- 5.3 Global Intraveno (IV) Iron Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Intraveno (IV) Iron Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Intraveno (IV) Iron Drugs Revenue by Region: 2027-2032
- 5.4 North America Intraveno (IV) Iron Drugs Market Facts & Figures by Country
- 5.4.1 North America Intraveno (IV) Iron Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Intraveno (IV) Iron Drugs Sales by Country (2021-2032)
- 5.4.3 North America Intraveno (IV) Iron Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Intraveno (IV) Iron Drugs Market Facts & Figures by Country
- 5.5.1 Europe Intraveno (IV) Iron Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Intraveno (IV) Iron Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Intraveno (IV) Iron Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Intraveno (IV) Iron Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Intraveno (IV) Iron Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Intraveno (IV) Iron Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Intraveno (IV) Iron Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Intraveno (IV) Iron Drugs Market Facts & Figures by Country
- 5.7.1 South America Intraveno (IV) Iron Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Intraveno (IV) Iron Drugs Sales by Country (2021-2032)
- 5.7.3 South America Intraveno (IV) Iron Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Intraveno (IV) Iron Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Intraveno (IV) Iron Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Intraveno (IV) Iron Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Intraveno (IV) Iron Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Intraveno (IV) Iron Drugs Sales by Type (2021-2032)
- 6.1.1 Global Intraveno (IV) Iron Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Intraveno (IV) Iron Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Intraveno (IV) Iron Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Intraveno (IV) Iron Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Intraveno (IV) Iron Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Intraveno (IV) Iron Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Intraveno (IV) Iron Drugs Sales by Application (2021-2032)
- 7.1.1 Global Intraveno (IV) Iron Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Intraveno (IV) Iron Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Intraveno (IV) Iron Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Intraveno (IV) Iron Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Intraveno (IV) Iron Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Intraveno (IV) Iron Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Intraveno (IV) Iron Drugs Value Chain Analysis
- 8.1.1 Intraveno (IV) Iron Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Intraveno (IV) Iron Drugs Production Mode & Process
- 8.2 Intraveno (IV) Iron Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Intraveno (IV) Iron Drugs Distributors
- 8.2.3 Intraveno (IV) Iron Drugs Customers
9 Global Intraveno (IV) Iron Drugs Analyzing Market Dynamics
- 9.1 Intraveno (IV) Iron Drugs Industry Trends
- 9.2 Intraveno (IV) Iron Drugs Industry Drivers
- 9.3 Intraveno (IV) Iron Drugs Industry Opportunities and Challenges
- 9.4 Intraveno (IV) Iron Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst